Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

S Negoro\textsuperscript{a,1}, N Masuda\textsuperscript{2}, Y Takada\textsuperscript{3}, T Sugiuara\textsuperscript{4}, S Kudoh\textsuperscript{5}, N Katakami\textsuperscript{6}, Y Ariyoshi\textsuperscript{7}, Y Ohashi\textsuperscript{8}, H Niitani\textsuperscript{9} and M Fukuoka\textsuperscript{10} for the CPT-11 Lung Cancer Study Group West

1Department of Clinical Oncology, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka 534-0021, Japan; 22nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Osaka 583-8588, Japan; 3Department of Respiratory Diseases and Radiology, Hyogo Medical Center for Adults, Hyogo 673-0021, Japan; 4Department of Respiratory Diseases, Aichi Cancer Center, Aichi 464-0021, Japan; 51st Department of Internal Medicine, Osaka City University Medical School, Osaka 545-8585, Japan; 6Department of Pulmonary Diseases, Kobe City General Hospital, Hyogo 650-0046, Japan; 71st Department of Respiratory Diseases, Aichi Prefectural Hospital, Aichi 444-0011, Japan; 8School of Health Sciences and Nursing, Faculty of Medicine, University of Tokyo, Tokyo 113-0033, Japan; 9The Tokyo Cooperative Oncology Group, Tokyo 105-0012, Japan; 10Department of Medical Oncology, Kinki University School of Medicine, Osaka 589-8511, Japan

To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to cisplatin+vindesine. A total of 398 patients with previously untreated NSCLC were randomised to receive cisplatin+CPT-11 (CPT-P), cisplatin+vindesine (VDS-P) or CPT-11 alone (CPT). In the CPT-P arm, CPT-11 60 mg m\textsuperscript{-2} was administered on days 1, 8 and 15, and cisplatin 80 mg m\textsuperscript{-2} was administered on day 1. In the VDS-P arm, cisplatin 80 mg m\textsuperscript{-2} was administered on day 1, and vindesine 3 mg m\textsuperscript{-2} was administered on days 1, 8 and 15. In the CPT arm, CPT-11 100 mg m\textsuperscript{-2} was administered on days 1, 8 and 15. The median survival time was 50.0 weeks for patients on CPT-P, 45.6 weeks for those on VDS-P and 46.0 weeks for those on CPT (P = 0.115, CPT-P vs VDS-P; P = 0.089, CPT vs VDS-P), and the hazard ratio was 0.85 (95% confidence interval (CI): 0.65–1.11) for CPT-P vs VDS-P and 0.83 (0.64–1.09) for CPT vs VDS-P. The response rate was 43.7% for patients on CPT-P, 31.7% for those on VDS-P and 20.5% for those on CPT. Major adverse reactions were grade 4 neutropenia observed in 37.5% and 8% of the patients on CPT-P, VDS-P and CPT, respectively; and grades 3 and 4 diarrhea observed in 12, 3 and 15% of the patients, respectively. CPT-P therapy produces comparable survival to VDS-P in patients with advanced NSCLC. CPT-11 monotherapy is not inferior to VDS-P in terms of survival. The CPT-11-containing regimen is one of the most efficacious and well tolerated in the treatment of advanced NSCLC.

British Journal of Cancer (2003) 88, 335–341. doi:10.1038/sj.bjc.6600725 www.bjcancer.com

© 2003 Cancer Research UK

Keywords: irinotecan; non-small-cell lung cancer; randomised phase III trial

In Japan, lung cancer is the leading cause of death among all the cancers, accounting for approximately 50,000 deaths annually (Statistics and Information Department, Ministry’s secretariat, Ministry of Health and Welfare, 2000). Non-small-cell lung cancer (NSCLC) accounts for more than 80% of primary lung cancers. Approximately two-thirds of NSCLC patients have advanced-stage cancer at presentation. The median survival time (MST) of the patients with advanced NSCLC, attained using the best available therapy (such as cisplatin-based chemotherapy), is typically 6–10 months, and most patients die of cancer within 1–2 years of diagnosis.

Irinotecan hydrochloride (CPT-11) is a water-soluble derivative of Camptotheca acuminata. Differing from conventional anti-tumour drugs in mechanism of action, CPT-11 produces its effect by inhibiting the synthesis of DNA and RNA through inhibition of DNA topoisomerase I (Kawato et al, 1991). CPT-11 has shown strong antitumour activity as a single agent against a broad spectrum of experimental tumours as well as against human malignancies.

The phase I clinical trial of CPT-11, in which CPT-11 was administered weekly, showed that the dose-limiting adverse effects were leucopenia and diarrhoea, and the recommended dose for the phase II monotherapy trial was 100 mg m\textsuperscript{-2} week\textsuperscript{-1} (Negoro et al, 1992). In the phase II clinical trial of CPT-11 monotherapy for patients with untreated advanced NSCLC, the response rate was 31.9% (23 out of 72 cases) and the MST was 42 weeks (Fukuoka et al, 1992).

In preclinical studies, CPT-11 was confirmed to act synergistically with cisplatin (CDDP) (Kudoh et al, 1993). Since CDDP is active against NSCLC and forms part of the standard therapeutic armamentarium employed in the treatment of NSCLC, a phase I trial of CPT-11+CDDP was initiated in 1991 (Masuda et al, 1992). From this trial, 60 mg m\textsuperscript{-2} CPT-11 on days 1, 8 and 15, and 80 mg m\textsuperscript{-2} CDDP on day 1 were recommended as the optimal dose
schedule. In 1992, a phase II trial of CPT-11+CDDP for untreated, stage IIIb or IV NSCLC was started employing this dose schedule; the response rate was 52% and the MST was 44 weeks (Masuda et al., 1998). These results suggested that CPT-11+CDDP could improve outcomes for patients with advanced NSCLC.

Previously, the National Cancer Institute of Canada (NCIC) Clinical Trials Group undertook a randomised study involving patients with NSCLC to determine whether there was a survival advantage for those patients treated with combination chemotherapy (vindesine (VDS)+CDDP or cyclophosphamide+doxorubicin (CDDP) over best supportive care (BSC). The results of that trial showed that the patients receiving VDS+CDDP had a statistically significant survival advantage over patients receiving BSC (Rapp et al., 1988). The VDS+CDDP regimen is one of the most widely used chemotherapeutic regimens for advanced NSCLC in Japan, and it was considered to be the most appropriate control regimen at the time when this study was initiated.

Based on the above results, we planned a phase III trial to compare CPT-11+CDDP and CPT-11 alone, with the control arm of VDS+CDDP, in order to elucidate the role of CPT-11 in advanced NSCLC.

MATERIALS AND METHODS

Eligibility criteria

Patients with histologically or cytologically confirmed and previously untreated NSCLC were enrolled into this trial. Patients with stage IIIb or IV cancer were eligible if they had measurable disease and a life expectancy of at least 3 months. Additional inclusion criteria were age (15–75 years old); a performance status (PS) of 0–2 on the Eastern Cooperative Oncology Group (ECOG) scale; and adequate functional indices for bone marrow (leucocyte count between $\geq 4000$ and $<12000/\text{mm}^3$, platelet count $\geq 100000/\text{mm}^3$, haemoglobin concentration $\geq 9.5 \text{ g dl}^{-1}$), liver (GOT and GPT $<100 \text{ IU} \text{l}^{-1}$, serum bilirubin $\leq 1.5 \text{ mg dl}^{-1}$), kidneys (serum creatinine $\leq$ the upper limit of normal) and lungs (PaO$_2$: at rest $\geq 8.0 \text{ kPa}$). Patients with other concurrent malignancies or a history of other malignancies, active infection, diarrhoea (watery stool) or intractable nausea and vomiting, or patients with signs or symptoms of pericardial effusion, pleural effusion or ascites, uncontrolled diabetes mellitus or symptomatic metastasis to the brain, were excluded. Informed consent was obtained from each patient before enrollment. EACH institutional review board for human experimentation approved the protocol of this study.

Randomisation

Eligible patients were randomly assigned to one of the three treatment arms by a centralised dynamic balancing method (a modified minimisation method) using stage (IIIB/IV), PS (0–1/2) and institution as balancing variables (Figure 1).

Treatment schedule

In the CPT-P arm, CPT-11 was given intravenously (i.v.) on days 1, 8 and 15 at a dose of $60 \text{ mg m}^{-2}$, and CDDP was given i.v. on day 1 at a dose of $80 \text{ mg m}^{-2}$. In the VDS-P arm, CDDP was given i.v. on day 1 at a dose of $80 \text{ mg m}^{-2}$ and VDS was given i.v. on days 1, 8 and 15 at a dose of $3 \text{ mg m}^{-2}$. In the control arm, CPT-11 was given i.v. on days 1, 8 and 15 at a dose of $100 \text{ mg m}^{-2}$. In each arm, one course of treatment lasted 4 weeks and each course was repeated once weekly. Computed tomography of the chest was repeated monthly. Any other examination was carried out when any clinical sign of disease progression was observed. The eligibility, evaluation and response of each patient were reviewed extramurally.

Figure 1 Study design. Patients enrolled were randomly allocated to receive CPT-P, VDS-P or CPT, after being stratified by PS, disease stage and institution. CPT-11 = irinotecan; CDDP = cisplatin; VDS = vindesine.

Dose modification

In all three arms, the dose of CPT-11 or VDS on day 8 or 15 was not given if the leucocyte count was less than $3000 \text{ mm}^{-3}$, platelet count was less than $100 000 \text{ mm}^{-3}$, body temperature was $37.5 ^\circ \text{C}$ or higher, or diarrhoea was grade 1 (frequency increased to two times or more daily, abdominal pain rated as mild or severe, or watery stool) or higher on the ECOG scale.

In each arm, before the next course was started, the leucocyte count had to be $4000 \text{ mm}^{-3}$ or more, platelet count had to be $100 000 \text{ mm}^{-3}$ or more, serum creatinine concentration had to be normal, and diarrhoea and fever should have disappeared. If there was a delay greater than 4 weeks caused by persistent toxicity, patients in each arm were to be withdrawn from the study.

If during the previous course, the leucocyte count had been less than $1000 \text{ mm}^{-3}$, platelet count less than $50 000 \text{ mm}^{-3}$ or diarrhoea had been grade 2 (stool passage increased to four times or more daily, stool passage at night or moderate abdominal pain, watery stool) or higher on the ECOG scale, the dose of CPT-11 was reduced to $50 \text{ mg m}^{-2}$ in the CPT-P arm, and to $80 \text{ mg m}^{-2}$ in the CPT arm. If during the previous course the serum creatinine concentration was more than 1.5 times the upper normal limit, the dose of CDDP was reduced to $60 \text{ mg m}^{-2}$ in the CPT-P arm and in the VDS-P arm.

Evaluation

This trial was independently monitored and performed according to GCP rules.

The primary end point of this study was overall survival. Response rate, duration of response, time to disease progression and toxicity were all secondary end points.

The stage of the disease was determined based on a complete medical history and physical examination, routine chest radiographs, fibroptic bronchoscopy, computed tomography of the head, chest and abdomen and bone scintigraphy. The staging estimates were made according to the international staging system (Mountain, 1986). Before the first course, the haemogram of each patient was determined and serum chemistry was used to check renal and hepatic functions, electrolytes and urinalysis. The haemogram was assessed at least twice a week, and serum chemistry, electrolytes, urinalysis and chest radiographs at least once weekly. Computed tomography of the chest was repeated monthly. Any other examination was carried out when any clinical sign of disease progression was observed. The eligibility, evaluability and response of each patient were reviewed extramurally.
The assessment of antitumour effects and toxicity was based on the WHO criteria (World Health Organization, 1979), but diarrhoea was evaluated in accordance with the ECOG common toxicity criteria (Oken et al, 1982). The overall survival was defined as the time from randomisation to the time of death from any cause or to last follow-up (cutoff date: 23 January 2000). The duration of each response was defined as the time from the initial response to disease progression. The time to disease progression was defined as the time from the start of treatment to disease progression.

Health-related quality of life (QOL) was assessed experimentally with a self-administered QOL questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) (Kurihara et al, 1999). The QOL-ACD was completed at baseline, every week during treatment and every month after treatment.

Statistical analysis

The superiority of CPT-P to VDS-P and the noninferiority of CPT to VDS-P were evaluated in terms of survival benefit.

The sample size was calculated on the basis that MSTs were expected to be 44, 30 and 35 weeks for the CPT-P, VDS-P and CPT arms, respectively (Einhorn et al, 1986), and both the accrual and follow-up intervals were 2 years.

By using the Schoenfeld and Richter equation (1982), the least number of patients to provide the 80% power needed to confirm the superiority of a regimen was calculated to be 115 per treatment arm for a one-sided 2.5% significance level test. Furthermore, the least number of deaths to provide the 80% power needed to prove the noninferiority for the upper limit at a 95% CI for the hazard ratio of CPT compared with VDS-P was lower than the upper equivalence margin, 1.33, and was estimated to be 81 per treatment arm at the one-sided 2.5% level. The significance levels for both inferences were set at 2.5% to control the overall type I error rate, and the one-sided statistical approach was employed to keep the simplicity and structural consistency of the statistical inferences for two study hypotheses. Taking ineligible patients into account, the sample size was set at 130 per treatment arm.

Cumulative survival curves were constructed as time-to-event plots by the Kaplan–Meier method (1958). Differences between the curves were tested for significance using one-sided log-rank statistics, and were estimated for noninferiority using the hazard ratio produced by the Cox regression model (Cox and Oakes, 1984). Furthermore, Cox regression models were used to evaluate treatment effects on survival, with adjustment for well-known prognostic factors: stage, PS, gender, weight loss, albumin and LDH (Albain et al, 1991; Espinosa et al, 1995; Paesmans et al, 1995; Ray et al, 1998). Response rates and toxicities were compared using the $\chi^2$ test. Subgroup analysis for survival was conducted by stage.

RESULTS

Patient characteristics

From July 1995 to January 1998, 398 patients from 41 centres were entered into this study. Of the 398 patients randomised, 18 patients did not meet the eligibility criteria. The reasons for exclusion were: early stage (<IIIIB) in five patients, previous treatment (OK-432, radiation therapy or surgery for local metastasis) in eight patients, other concurrent malignancies in two patients, age (>75 years) in one patient, presence of pericardial effusion in one patient, and leucocyte count (>12 000 mm$^{-3}$) in one patient.

The patient characteristics at baseline are listed in Table 1. The median age of the patients was 62–64 years and the range was 35–75 years. A total of 62% of the patients had adenocarcinoma, 31% had squamous cell carcinoma, 37% had stage IIB disease and 94% of the patients had a good performance status (PS 0–1). The three treatment groups were well balanced for all baseline characteristics.

| Table 1 Patient characteristics at baseline |
|---------------------------------------------|
|                | CPT-P | VDS-P | CPT |
| Patients entered | 133   | 133   | 132 |
| Eligible patients* | 129   | 122   | 129 |
| Gender          |       |       |     |
| Male            | 98    | 98    | 96  |
| Female          | 31    | 24    | 33  |
| Age (years)     |       |       |     |
| o–49            | 10    | 19    | 22  |
| 50–59           | 36    | 29    | 30  |
| 60–69           | 58    | 51    | 52  |
| 70+             | 25    | 23    | 25  |
| Median (range)  | 64 (36–75) | 64 (35–75) | 62 (35–75) |
| PS              |       |       |     |
| 0–1             | 121   | 115   | 121 |
| 2               | 8     | 7     | 8   |
| Stage           |       |       |     |
| IIB             | 49    | 46    | 44  |
| IV              | 80    | 76    | 85  |
| Histology       |       |       |     |
| Adenocarcinoma  | 78    | 73    | 84  |
| Squamous cell   | 37    | 45    | 34  |
| carcinoma       |       |       |     |
| Others          | 14    | 4     | 11  |
| Weight loss     |       |       |     |
| No              | 74    | 67    | 77  |
| Less than 5%    | 10    | 14    | 9   |
| 5% or more      | 27    | 30    | 29  |
| Unknown         | 18    | 11    | 14  |

*Patients who were used to evaluate survival.

CPT=irinotecan; P=cisplatin; VDS=vindesine; PS=performance status.

Treatment administration

Three patients received no treatment (one patient in the CPT-P arm and two patients in the CPT arm), two patients in the VDS-P arm received vincristine (VCR) instead of VDS, one patient in the CPT arm exceeded the daily dose of CPT-11 and CDDP, and one patient in the CPT-P arm received CDDP on days 1 and 8. These seven patients were included in the survival analysis, but excluded from response and toxicity analysis. In all, 109 of the 126 patients on CPT-P (87%), 97 of the 120 patients on VDS-P (81%) and 101 of the 127 patients on CPT (80%) received more than two courses of treatment, and 22 patients (18%) on CPT-P, 15 patients (13%) on VDS-P and 20 patients (16%) on CPT received more than four courses of treatment. The median number of courses administered per patient was 3 for CPT-P and 2 for both VDS-P and CPT. The number of treatment courses varied from one to six in each arm. In the CPT-P, VDS-P and CPT arms, 23, 10 and 16 patients were withdrawn from the study because of toxicities (including duplications); 28, 44 and 51 patients because of disease progression; 37, 27 and 19 patients due to patient’s refusal; 10, 19, and 22 patients because of aggravated clinical symptom; 50, 32 and 28 patients because of other reasons, respectively. Most patients could repeat treatment courses every 28 days irrespective of the arm.

The number of treatment courses in which CPT-11 or VDS was administered on days 1, 8 and 15 totaled 164 courses (50% of a
Survival

The survival curves for all eligible patients are shown in Figure 2. The MST was 50.0 weeks for patients on CPT-P, 45.6 weeks for those on VDS-P and 46.0 weeks for those on CPT, and the 1- and 2-year survival rates were 46.5 and 19.4% for patients on CPT-P, 38.3 and 18.7% for those on VDS-P, and 41.8 and 21.9% for those on CPT. The one-sided log-rank test comparing the survival of patients who received CPT-P vs those treated with VDS-P yielded a $P$-value of 0.115, and when the survival of patients treated with CPT was compared with that of patients treated with VDS-P, the $P$-value was 0.089. The hazard ratio was 0.85 (95% CI: 0.65–1.11) for CPT-P vs VDS-P and 0.83 (95% CI: 0.64–1.09) for CPT vs VDS-P.

Subgroup analyses for survival were conducted using stage as one of the balancing variable factors (Figure 3). Among patients with stage IIIB disease (Figure 3A), the MST was 49.7 weeks for those on CPT-P, 60.6 weeks for those on VDS-P and 63.3 weeks for those on CPT. The hazard ratio was 1.24 (95% CI: 0.81–1.91, one-sided, log-rank test: $P = 0.838$) for CPT-P vs VDS-P and 0.99 (95% CI: 0.63–1.56, one-sided, log-rank test: $P = 0.483$) for CPT vs VDS-P. Among patients with stage IV disease (Figure 3B), the MST was 50.0 weeks for those on CPT-P, 36.4 weeks for those on VDS-P and 42.1 weeks for those on CPT. The hazard ratio was 0.64 (95% CI: 0.46–0.89, one-sided, log-rank test: $P = 0.004$) for CPT-P vs VDS-P and 0.70 (95% CI: 0.50–0.98, one-sided, log-rank test: $P = 0.018$) for CPT vs VDS-P.

The Cox proportional hazards model was used to adjust for and determine the impact of prognostic factors and treatment on survival (Table 2). Predictive factors for improved survival included early clinical stage, no weight loss, normal LDH, normal albumin and better PS, each of which was significantly associated with longer survival.

Response

Objective response data are listed in Table 3. The overall response rate was 43.7% for patients on CPT-P, 31.7% for those on VDS-P and 20.5% for those on CPT (two-sided, $\chi^2$ test: $P < 0.001$). The median duration of response for responders was 141 days for patients on CPT-P, 121 days for those on VDS-P, and 117 days for those on CPT (two-sided, log-rank test: $P = 0.601$). The median time to progression for the patients included in the efficacy analysis was 148 days for patients on CPT-P, 117 days for those on VDS-P and 100 days for those on CPT (two-sided, log-rank test: $P = 0.091$).

Toxicity

Major adverse reactions are listed in Table 4. Grade 4 neutropenia was observed significantly more frequently in the VDS-P arm than in the CPT-P and CPT arms, both of which contain CPT-11 ($P < 0.001$). Grade 4 thrombocytopenia was more frequent in the CPT-P arm, but there were no thrombocytopenia-related complications. Diarrhoea was the main nonhaematological sign of toxicity of the regimens containing CPT-11 (CPT-P and CPT); these two regimens were associated with a significantly higher occurrence of grades 3 and 4 diarrhoea as compared with the VDS-P regimen ($P = 0.008$). The regimens containing CDDP (CPT-P, VDS-P) were associated with a significantly higher occurrence of grade 3 nausea/vomiting as compared with the CPT alone regimen ($P = 0.001$). Peripheral neurological symptoms were observed significantly more frequently in the VDS-P group than in the other two groups ($P < 0.001$).
### Table 2 Cox proportional hazards model

| Variable       | Hazard ratio | 95% CI    | p-value |
|----------------|--------------|-----------|---------|
| Regimen        |              |           |         |
| CPT-P/VDS-P    | 0.80         | 0.60–1.07 | 0.1341  |
| CPT/VDS-P      | 0.88         | 0.66–1.16 | 0.3557  |
| Stage (IVb)    | 1.70         | 1.32–2.19 | 0.0001  |
| PS (2/1/0)     | 1.40         | 1.08–1.80 | 0.0098  |
| Gender (male/female) | 1.29 | 0.96–1.73 | 0.0922  |
| Weight loss (≥5%/<5%) | 2.00 | 1.53–2.60 | 0.0001  |
| Albumin (<40g/dL/<40g/dL) | 1.53 | 1.17–1.98 | 0.0016  |
| LDH (>400IU/L/<400IU/L) | 1.54 | 1.17–2.04 | 0.0021  |

CI: confidence interval; CPT=irinotecan; P=cisplatin; VDS=vindesine; PS=performance status; LDH=lactic acid dehydrogenase.

### Table 3 Objective response

| n   | CR | PR | NC | PD | NE | ORR (%) |
|-----|----|----|----|----|----|---------|
| CPT-P | 126 | 3  | 52 | 51 | 17 | 3       | 43.7    |
| VDS-P | 120 | 1  | 37 | 54 | 25 | 3       | 31.7    |
| CPT   | 127 | 3  | 25 | 66 | 33 | 2       | 20.5    |

n: number of assessable patients, CR: complete response, PR: partial response, NC: no change, PD: progressive disease, NE: not evaluable, ORR: objective response rate; CPT=irinotecan, P=cisplatin, VDS=vindesine.

### Table 4 Major adverse reactions

|                                                                 | CPT-P (n=126) | VDS-P (n=120) | CPT (n=127) |
|-----------------------------------------------------------------|---------------|---------------|-------------|
| Leucopenia (grade 4)                                           | 8 (6%)        | 4 (3%)        | 2 (2%)      |
| Neutropenia (grade 4)                                          | 46 (37%)      | 65 (54%)      | 10 (8%)     |
| – Febrile neutropenia                                         | 13 (10%)      | 13 (11%)      | 8 (6%)      |
| Thrombocytopenia (grade 4)                                    | 4 (3%)        | 1 (1%)        | 0 (0%)      |
| Anaemia (grade 4)                                             | 2 (2%)        | 1 (1%)        | 1 (1%)      |
| GOT (grade 3 and 4)                                           | 0 (0%)        | 1 (1%)        | 0 (0%)      |
| GPT (grade 3 and 4)                                           | 1 (1%)        | 1 (1%)        | 0 (0%)      |
| BUN (grades 3 and 4)                                          | 2 (2%)        | 2 (2%)        | 0 (0%)      |
| Creatinine (grades 3 and 4)                                   | 0 (0%)        | 1 (1%)        | 0 (0%)      |
| Diarrhoea (grades 3 and 4)                                    | 15 (12%)      | 4 (3%)        | 19 (15%)    |
| Nausea/vomiting (grades 3 and 4)                              | 41 (33%)      | 27 (23%)      | 12 (9%)     |
| Infection (grades 3 and 4)                                    | 4 (3%)        | 1 (1%)        | 6 (5%)      |

CPT=irinotecan; P=cisplatin; VDS=vindesine; GOT=glutamic oxaloacetic transaminase; GPT=glutamic pyruvic transaminase; BUN=blood urea nitrogen.

Second-line treatment

Among patients with stage IIIb disease, 45% on CPT-P, 61% on VDS-P and 59% on CPT were subsequently treated with thoracic irradiation.

Among patients with stage IV disease, 25% on CPT-P, 26% on VDS-P and 40% on CPT were subsequently treated with other chemotherapeutic regimens. In particular, seven patients on CPT-P, nine patients on VDS-P and 10 patients on CPT were subsequently treated with docetaxel (DTX) monotherapy or DTX-containing regimens.

**DISCUSSION**

Since 1990, newer agents such as CPT-11, paclitaxel (PTX), DTX, gemcitabine (GEM) and vinorelbine (VNB) have shown response rates of 20% or more when used alone in previously untreated NSCLC (Bunn and Kelly, 1998).

Except for CPT-11, all four chemotherapeutic agents have been examined in many phase III trials in patients with advanced NSCLC and their roles have been mostly elucidated. No trial has been conducted, however, in order to establish the role of CPT-11 in advanced NSCLC. The present clinical trial was the first phase III study of CPT-11 in patients with advanced NSCLC. We planned this phase III trial in order to verify (1) whether CPT-P significantly prolongs the survival time and (2) whether CPT alone is not inferior in terms of the survival time, as compared with VDS-P, one of the most commonly used chemotherapeutic regimen that has been used in advanced NSCLC.

The first results showed that CPT-P did not significantly prolong the survival time compared with VDS-P. Previous studies of PTX (Belani et al, 1998; Giaccone et al, 1998; Bonomi et al, 2000), DTX (Kubota et al, 2002), GEM (Cirino et al, 1999) and VNB (Le Chevalier et al, 1994; Martoni et al, 1998) were for comparison of a platinum compound plus a new agent vs an old platinum-based chemotherapy. Only the studies by Le Chevalier et al (1994) and Kubota et al (2002) reported significant differences in terms of survival based on the analysis scheduled in the protocol. Similar to the present trial, there was no significant prolongation of the survival time in other studies. There were meta-analyses of these results that reported the superiority of the regimen of platinum compounds plus a new agent (Baggstrom et al, 2002; Yana et al, 2002).

The second results showed that CPT-11 alone was not inferior to VDS-P in terms of the survival time. In a study of Le Chevalier et al (1994), that compared three groups (VNB and CDDP vs VDS and CDDP vs VNB alone), similar to the present trial, the survival was also similar between VNB alone and VDS-P. Toxicity on CPT alone was mild except for slightly frequent diarrhoea. Based on these results, chemotherapy with the new single agent may be considered for patients who are unable to receive CDDP-containing regimens because it can produce the similar survival to conventional platinum-based combinations, and toxicity is relatively mild.

In the subgroup analyses according to the stage, in stage IV patients, the MST was 50.0 weeks on CPT-P and 36.4 weeks on VDS-P, with the CPT-P being superior to the VDS-P with respect to survival prolongation (one-sided, log-rank test: P = 0.004). CPT-11 alone also significantly prolonged the survival time in patients with stage IV NSCLC compared with VDS-P. Among stage IV patients, there was no bias in terms of background factors including PS (the ratio of PS 0–1 patients was 96% on CPT-P, 92% on VDS-P and 94% on CPT), gender (male ratio was 69% on CPT-P, 79% on VDS-P and 68% on CPT) and the rate of weight loss at baseline (the ratio of patients without weight loss was 63% on CPT-P, 58% on VDS-P and 55% on CPT). There was no bias in the content of second-line treatment among the treatment arms. These are just the results of the subgroup analyses and their significance should be shown in another research.
The results of subgroup analyses differed between stage IIIB and stage IV patients. Between-arm differences in the ratio of patients receiving second-line chest irradiation might, in part, lead to such differences. In the present trial, there was no eligibility criterion to restrict stage IIIB patients for whom thoracic irradiation was indicated. Therefore, the possibility could not be ruled out that the present trial included patients who were not suitable for research purely comparing chemotherapeutic agents as in the case of this trial. This might be one reason for different results between stages IIIB and IV patients in the subgroup analyses. In future research, the inclusion of stage IIIB patients should be limited to patients for whom definitive thoracic radiation is not indicated.

Comparing survival between CPT-P and CPT-11 alone, although this was not planned, no significant difference was shown between the two arms (one-sided, log-rank test: \( P = 0.587 \)). The hazard ratio for CPT vs CPT-P was 1.03 (95% CI: 0.79 – 1.34).

The overall response rate in this study was 43.7% on CPT-P, 31.7% on VDS-P and 20.5% on CPT (two-sided, \( \chi^2 \) test: \( P < 0.001 \)). This significant difference in the response rate did not lead to significant differences in the survival time. Similar results have been frequently reported in comparative studies of chemotherapeutic agents in advanced NSCLC. Various known and unknown prognostic factors were involved in this result. Of them, the major factor is that complete response (CR) is obtained only in small numbers of NSCLC patients receiving chemotherapy. In the present trial, the CR rate was just 2.4% (three out of 126) in the CPT-P arm, 0.8% (one out of 120) in the VDS-P arm and 0.8% (one out of 127) in the CPT arm.

The present trial allowed including patients with PS 2. This resulted in the inclusion of approximately 6% of PS 2 patients in each treatment arm. In a large-scale ECOG study (E1594) by Schiller et al. (2002), the accrual of patients with PS 2 was discontinued owing to the high rate of serious adverse events. This fact was disclosed in May 1999 (Johnson et al., 1999), and our trial completed patient registration before this time, so it was impossible to exclude PS 2 patients. Inclusion of PS 2 patients had no significant impact on the results of the present trial because the number of such patients was small and they were distributed evenly to the three arms according to baseline demographic factors.

Neutropenia and neurotoxicity were more frequent in the non-CPT-containing VDS-P arm, than in the CPT-containing CPT-P and CPT arms. Nausea/vomiting was more frequent in the CDDP-containing CPT-P and VDS-P arms, than in the non-CDDP-containing CPT arm. Diarrhoea was more frequent in the CPT-containing arm than in the VDS-P arm. In the present trial, there were no deaths associated with the treatment in the CPT-P arm, but one patient in the CPT arm developed diarrhoea after recovery from myelosuppression and subsequently died from infection. In this patient, it was not clear whether the source of infection was the bowel or the tip of the catheter. In 10 patients treated with the regimen containing CPT-11 who developed grade 3 or higher infection, seven patients developed diarrhoea coincidently with myelosuppression, which suggested enteritis as the source of infection. Infection was avoided in many patients by taking proactive measures against aggravation of diarrhoea and taking early anti-infection measures.

In conclusion, the response rate was significantly higher in patients with CPT-P therapy compared with VDS-P, and the survival time and toxicity were comparable, although this therapy failed to demonstrate significant survival prolongation. Based on these results, a large-scale randomised phase III trial comparing CPT-P as the control regimen with three new drugs (NVB, PTX, GEM) containing platinum-based doublets is currently underway in Japan. CPT-11 monotherapy produced survival result that was not inferior to that obtained with VDS-P, but produced less toxicity. Further studies are necessary to determine the significance of CPT-11 monotherapy in the treatment of NSCLC. This randomised phase III trial has demonstrated that the regimen containing CPT-11 is one of the most active and well tolerated in the treatment of advanced NSCLC.

ACKNOWLEDGEMENTS

We thank Mrs Akira Sahashi and Tomoji Miyazaki for their assistance in data collection and analysis. We are also grateful to Drs Tetsuo Taguchi, Kiyokazu Yoshida, Shigeru Tukagoshi and Yuhei Miyata for the kind advice they provided while serving on an advisory committee set up to assist this study.

This work was supported in part by grants from Yakult Honsha Co., Ltd, Tokyo, Japan, and Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan.

REFERENCES

Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618 – 1626

Baggstrom MQ, Socinski MA, Hensing TA, Poole C (2002) Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 21: 306B (abstract)

Belani CP, Natale RB, Lee JS, Socinski M, Robert F, Waterhouse D, Rowland K, Ansari R, Lilienbaum R, Sridhar K (1998) Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 455A (abstract)

Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowsinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623 – 631

Bunn Jr PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087 – 1100

Cox DR, Oakes D (1984) Analysis of Survival Data. Chapman & Hall: London

Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaiol A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tomato M (1999) Gemicitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522 – 3530

Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Draega R, Songer J, Fisher W, Stephens D, Hui S (1986) Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037 – 1043

Esipona E, Felui J, Zamora P, Gonzalez Baron M, Sánchez JJ, Ordoñez A, Esipona J (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12: 67 – 76

Fukuo M, Nishitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiyaki Y, Kuriyama T, Aiyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (2003) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16 – 20

British Journal of Cancer (2003) 88(3), 335 – 341 © 2003 Cancer Research UK
Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoelsen Q, Curran D, Sahmoud T, Postmus PE (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133 – 2141

Johnson DH, Zhu J, Schiller J, Belani C, Langer CJ, Krook JE, Harrington D, Sandler AB (1999) A randomized phase III trial in metastatic non-small cell lung cancer outcome of PS 2 patients (PTS): an Eastern Cooperative group trial (ECOG). Proc Am Soc Clin Oncol 18: 461a (abstract)

Kaplan EL, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457 – 481

Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular rules of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187 – 4191

Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiuira T, Kawahara M, Yokoyama A, Nishiwaki Y, Ohashi Y, Niitani H (2002) Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 296a (abstract)

Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro S, Matsui S, Takifuji N, Morino H, Fukuoka M (1993) Enhanced antitumour efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84: 203 – 207

Kurihara M, Shimizu H, Tsuibo K, Kobayashi K, Murakami M, Eguchi K, Shimozuma K (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy: psychooncology. Jpn J Cancer Res 90: 355 – 363

Le Chevalier T, Brigand D, Douljard YJ, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chompy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360 – 367

Martoni A, Guaraldi M, Piana E, Ambrosini G, Sarabba G, Farris A, Panetti F (1998) Multicenter randomized clinical trial on high-dose epirubicin plus cisplatin versus vinorelbine plus cisplatin in advanced non small cell lung cancer. Lung Cancer 22: 31 – 38

Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Martoni A, Guaraldi M, Piana E, Strocchi E, Petralia A, Busutti L, Preti P, Robustelli G, Raimondi M, Ferrara G, Palomba G, Lelli G, Piceve V, Recaldi E, Caffe O, Ambrosini G, Sarabba G, Farris A, Panetti F (1998) Multicenter randomized clinical trial on high-dose epirubicin plus cisplatin versus vinorelbine plus cisplatin in advanced non-small cell lung cancer. Lung Cancer 22: 31 – 38

APPENDIX

The following members and institutions participated in this study: S Nakamura, 4th Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; M Kawahara, Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Osaka; S Yokota, Department of Internal Medicine, Toneyama National Hospital, Osaka; T Nakano, 3rd Department of Internal Medicine, Hyogo College of Medicine, Hyogo; N Hara, Research Institute for Diseases of the Chest, Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka; H Senba, Division of Respiratory Diseases, Kumamoto Regional Medical Care Center, Kumamoto; J Ohata, Department of Respiratory Diseases, Shimonoseki Kosei Hospital, Yamaguchi; T Sawa, Division of Respiratory Medicine, Gifu Municipal Hospital, Gifu; K Bando, Department of Respiratory Medicine, Saiseikai Nakatsu Hospital, Osaka; M Takada, Department of Respiratory Diseases, Izumisano Municipal Hospital, Osaka; T Yano, Department of Internal Medicine, Osaka Prefectural General Hospital, Osaka; S Sakai, Department of Respiratory Diseases, Japanese Red Cross Nagoya First Hospital, Aichi; M Oka, 2nd Department of Internal Medicine, School of Medicine, Nagasaki University, Nagasaki; T Igarashi, 2nd Department of Internal Medicine, Osaka Posts and Telecommunications Hospital, Osaka; H Nishiyama, Department of Respiratory Medicine, Japanese Red Cross Society Wakayama Medical Center, Wakayama; T Kamei, Department of Internal Medicine, Kagawa Prefectural Hospital, Kagawa; Department of Internal Medicine, Saga Medical School, Saga; J Araki, Department of Internal Medicine, Sasebo City General Hospital, Nagasaki; M Fujimura, 3rd Department of Internal Medicine, School of Medicine, Kanazawa University, Ishikawa; T Hosokawa, Department of Respiratory Medicine, Wakayama Rosai Hospital, Wakayama; H Yanagawa, 3rd Department of Internal Medicine, School of Medicine, The University of Tokushima, Tokushima; T Isobe, 2nd Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima; T Tsuya, Department of Pulmonary Diseases, Chugoku Rosai Hospital, Hiroshima; A Motohiro, Department of Surgery, National Mina-mifukuoka Chest Hospital, Fukuoka; H Yamamoto, Department of Pulmonary Diseases, Aso Cement Izuka Hospital, Fukuoka; M Ichiki, 1st Department of Internal Medicine, Kurume University, School of Medicine, Fukuoka; S Hayasaka, Department of Internal Medicine, Kumamoto Chuo Hospital, Kumamoto; T Kanda, Department of Internal Medicine, Nagasaki Municipal Citizens Hospital, Nagasaki; H Fujiiwara, 2nd Department of Internal Medicine, Gifu University School of Medicine, Gifu; M Kono, Department of Radiology, Kobe University School of Medicine, Hyogo; K Daido, Department of Respiratory Diseases, Hiroshima Red Cross Hospital, Hiroshima; Y Ichinose, Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka; Y Yamaji, Respiratory Division, Mitoyo General Hospital, Kagawa.